Skip to main content
65°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
86.62
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Novavax Remains a Risk-On Stock in a Risk-Off Market
September 22, 2022
NVAX is a risk-on stock at a time investors are turning to risk-off assets. This article looks to see if Novavax still presents an opportunity for investors
Via
MarketBeat
Topics
Earnings
Exposures
Financial
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines
September 13, 2022
Via
JCN Newswire
Exposures
COVID-19
Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214
September 12, 2022
Via
ACCESSWIRE
Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines
September 12, 2022
Via
ACN Newswire
Exposures
COVID-19
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines
September 09, 2022
Via
ACN Newswire
Exposures
COVID-19
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
September 08, 2022
Via
ACCESSWIRE
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine
September 01, 2022
Via
ACCESSWIRE
Moderna to Host R&D Day on Thursday, September 8, 2022
August 29, 2022
Via
ACCESSWIRE
Moderna to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
Via
ACCESSWIRE
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union
September 01, 2022
Via
ACCESSWIRE
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
August 31, 2022
Via
ACCESSWIRE
Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia
August 30, 2022
Via
ACCESSWIRE
Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
August 29, 2022
Via
ACCESSWIRE
Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
August 26, 2022
Via
ACCESSWIRE
Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada
August 22, 2022
Via
ACCESSWIRE
Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 03, 2022
Via
ACCESSWIRE
Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
August 23, 2022
Via
ACCESSWIRE
James Mock Joins Moderna as Chief Financial Officer
August 17, 2022
Via
ACCESSWIRE
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK
August 15, 2022
Via
ACCESSWIRE
Two Appealing Biotech Stocks for Two Distinct investors
August 08, 2022
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses
August 08, 2022
Via
ACCESSWIRE
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
August 11, 2022
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by...
Via
FinancialNewsMedia
Exposures
COVID-19
3 Health Care Stocks in Great Financial Health
August 02, 2022
Health care’s potential to do better in both up and down markets makes it a valuable part of a long-term investment strategy.
Via
MarketBeat
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
July 29, 2022
Via
ACCESSWIRE
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
July 29, 2022
New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Is Moderna's Cheaper Valuation A Buying Signal?
July 28, 2022
Moderna is one of the least expensive companies in the S&P 500 in terms of valuation. In this article, we'll examine other aspects of the company.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
July 22, 2022
Via
ACCESSWIRE
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
July 22, 2022
CAMBRIDGE, MA / ACCESSWIRE / July 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Therapeutic Goods Administration Grants Provisional Approval for Moderna's COVID-19 Vaccine in Children Aged Six Months to Five Years
July 19, 2022
Via
ACN Newswire
Exposures
COVID-19
Is it Time to Cash Out Novavax Stock?
July 19, 2022
Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S.
Via
MarketBeat
Exposures
COVID-19
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.